𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo

✍ Scribed by Dr. C. Pacchetti; E. Martignoni; P. Bruggi; L. Godi; B. Aufdembrinke; C. Miltenburger; B. Voet; G. Nappi

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
290 KB
Volume
8
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours “off” decreased at weeks 6 and 12 (p < 0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score “on” and “off” (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing‐off increased; no one dropped out because of side effects. This 3‐month doubleblind study showed that TER, added to stable doses of L‐dopa, may have slight antiparkinsonian efficacy.

📜 SIMILAR VOLUMES

Placebo-controlled, double-blind dose-fi
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients
✍ Yoshikuni Mizuno; Ichiro Kanazawa; Sadako Kuno; Nobuo Yanagisawa; Mitsutoshi Yam 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 1 views

## Abstract We conducted a multicenter randomized, placebo‐controlled double‐blind parallel‐group study in Japanese Parkinson's disease (PD) patients with wearing‐off motor fluctuations to determine the clinical efficacy and safety of entacapone as an adjunct to concomitant treatment with levodopa

Double-blind study comparing doxercalcif
Double-blind study comparing doxercalciferol and placebo in vitamin D-replete CKD patients
✍ Anita Patel; John Robertson; Christine Darwin; Harold Locay; Ramon Añel; Sara En 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 91 KB

OBJECTIVE: No well-controlled studies of the safety and effi cacy of active vitamin D analogues have been conducted in vitamin D-replete (25-hydroxyvitamin D Ն 30 ng/mL) patients. This study assessed the safety and effi cacy of doxercalciferol in vitamin D-replete patients with secondary hyperparath

Terlipressin in bleeding esophageal vari
Terlipressin in bleeding esophageal varices: A placebo-controlled, double-blind study
✍ Siegfried Walker M.D.; Adolf Stiehl; Richard Raedsch; Burkhard Kommerell 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB 👁 1 views

The effect of terlipressin (N-a-triglycyl-8-lysinevasopressin) in bleeding esophageal varices was evaluated in a prospective placebo-controlled study. Fifty bleeding episodes from esophageal varices in 34 patients were randomized. Standard therapy with transfusions, fluid and electrolyte correction,

Sulpiride and placebo in depressed elder
Sulpiride and placebo in depressed elderly outpatients: A double-blind study
✍ Sirkka-Liisa Kivelä; Erkki Lehtomäki 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 423 KB 👁 2 views

In a controlled double-blind study, sulpiride 10G200mg daily or placebo was administered over a five-month period to 22 and 24 depressive elderly outpatients. The majority of the patinets in both groups were diagnosed as suffering from relatively mild degrees of depression, i.e. from dysthymic disor

Mirtazapine in essential tremor: A doubl
Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study
✍ Rajesh Pahwa; Kelly E. Lyons 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

## Abstract We sought to determine whether mirtazapine is safe and well‐tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double‐blind, placebo‐controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or